Jack Chiang’s Bio

Background

Jack Chiang is a research scientist in the Department of Biomedical informatics at The Ohio State Wexner Medical Center. He received his Ph.D. in Bioinformatics in January 2018 from Indiana University.  He had previously received his B.S. in Biomedical Engineering from Purdue University in May of 2009.  Dr. Chiang’s record of publication in respected journals and conference proceedings stretches back to at least 2012.  Dr. Chiang’s entire postsecondary education has been in the United States, and he has been living and working here for over 16 years now.

Biomedical informatics (or “bioinformatics”) is the study of development and improvement of methods for storage, retrieval, and analysis of biological and biomedical data.  This type of data analysis — often on a massive scale — is increasingly important for use in epidemiological studies, clinical studies, and drug design and development.  In this context, Dr. Chiang’s research encompasses a range of data analysis and modeling issues related to biological database development, algorithms and machine learning\artificial intelligence for drug discovery, and network modeling for pathobiology applications.

Education

Ph.D., Bioinformatics, Indiana School of Informatics and Computing, 2018

Research Interests

  • Clinical Pharmacokinetics and Pharmacodynamics for Drug-Drug Interaction
  • Longitudinal data analysis
  • Pharmacoepidemiology
  • Machine learning/ artificial intelligence algorithm
  • Relational/Non-relational biological database development

Selected Publications

  1. Chiang, C. W., P. Zhang, M. Donneyong, Y. Chen, Y. Su, L. J. C. P. Li and S. Pharmacology (2021). “Random Control Selection for Conducting High‐throughput Adverse Drug Events Screening using Large‐scale Longitudinal Health Data.”
  2. Chiang, C. W., P. Zhang, X. Wang, L. Wang, S. Zhang, X. Ning, L. Shen, S. K. Quinney, L. J. C. P. Li and Therapeutics (2018). “Translational high‐dimensional drug interaction discovery and validation using health record databases and pharmacokinetics models.”  103(2): 287-295.
  3. Zhang, P., C. Chiang, S. Quinney, M. Donneyong, B. Lu, L. Huang and F. J. m. Cheng (2020). “The Concurrent Initiation of Medications Is Associated with Discontinuation of Buprenorphine Treatment for Opioid Use Disorder.”